Previous close | 0.1633 |
Open | 0.1616 |
Bid | 0.1610 x 800 |
Ask | 0.1713 x 1000 |
Day's range | 0.1610 - 0.1750 |
52-week range | 0.1400 - 0.8900 |
Volume | |
Avg. volume | 483,985 |
Market cap | 6.089M |
Beta (5Y monthly) | 0.10 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 29 Apr 2024 - 05 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Reaffirms commitment to regaining compliance with the NYSE American continued listing standardsDURHAM, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), received an official notice of noncompliance (the “NYSE American Notice”) from NYSE Regulation stating that the Company is not in compliance with NYSE American LLC (“NYSE American” or the “Exchange”) continued listing standards (the “Fi
DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been awarded a contract in excess of $1 million with an NIH-funded researcher at a major university. The program involves process optimization and development of a therapeutic antibody, which Scorpius will manufacture for preclinical studies. The work will be conducted in the Company’s state-of-the-art
Provides Access to Growth Funding and Enhanced Access to Federal ProjectsDURHAM, N.C., March 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has been accepted into the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), a part of the National Biopharmaceutical Manufacturing Partnership. The BioMap-Consortium has a $20 billion funding ceiling, throu